

Eine Recherche des British Medical Journey (BMJ) in Sachen Leitlinien

Ein monströser Interessenkonflikt

Literaturverzeichnis

1. Læger til salg [Doctors For Sale]. TV 2. 2024. <https://play.tv2.dk/serie/laeger-til-salg-tv2>
2. Fox K, Garcia MAA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:-81. pmid: 16735367. doi: 10.1093/eurheartj/ehl001
3. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:-16. pmid: 18757088. doi: 10.1016/S0140-6736(08)61170-8
4. European Society of Cardiology. Treatment Appears To Reduce Heart Attack Risk And Revascularisation In Stable Coronary Patients. Science Daily. 2 Sep 2008. <https://www.sciencedaily.com/releases/2008/08/080831211806.htm>
5. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014;371:-9. pmid: 25176136. doi: 10.1056/NEJMoa1406430
6. European Medicines Agency. European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine). 2015. <https://www.ema.europa.eu/en/medicines/human/referrals/corlentor-procoralan>
7. Badu-Boateng C, Jennings R, Hammersley D. The therapeutic role of ivabradine in heart failure. Ther Adv Chronic Dis 2018;9:-207. pmid: 30364460. doi: 10.1177/2040622318784556
8. Martin J. Integrity and the European society of cardiology. Lancet 2015;385:. pmid: 25706849. doi: 10.1016/S0140-6736(15)60116-7
9. Boseley S. Junket time in Munich for the medical profession—and it's all on the drug firms. Guardian. 5 Oct 2004. <https://www.theguardian.com/uk/2004/oct/05/highereducation.businessofresearch>
10. European Society of Cardiology. Past Presidents' Committee. <https://www.escardio.org/aboutus/how-we-work/our-board-and-leadership/past-presidents-committee/>

11. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. *JAMA* 2002;287:-7. pmid: 11829700. doi: 10.1001/jama.287.5.612
12. General Medical Council. Good Medical Practice. 2001. https://www.gmc.uk.org/cdn/documents/good-medical-practice-2001_pdf-55612679.pdf
13. European Society of Cardiology. ESC declaration and management of conflict of interest policy. Appendix 3. Rules for assessment of DOI. <https://dam-assets.escardio.org/download/ecc7c546d03111f0bb09b652c04c9087>
14. Hinton J, Reeves T, Shah BN. Analysis of conflicts of interest among authors and researchers of European clinical guidelines in cardiovascular medicine. *Clinical Medicine* 2021;21:-70. doi: 10.7861/clinmed.2020-0552
15. CMS Open Payments. openpaymentsdata.cms.gov.
<https://openpaymentsdata.cms.gov>
16. Accueil—Transparence Santé.
<https://www.transparence.sante.gouv.fr/pages/accueil/>
17. Macleod S. The Independent Medicines and Medical Devices Safety review: Regulatory reform and remedies. *Law Tech Hum* 2023;5:-20. doi: 10.5204/lthj.3083
18. Ozieranski P, Larkin J, Rickard E, Ozaki A, Mulinari S, MacLeod R, et al. Protecting patients and the NHS through full transparency in industry-NHS collaborations. Oct 2024. <https://www.bath.ac.uk/publications/protecting-patients-and-the-nhs-through-full-transparencyin-industry-nhs-collaborations/attachments/protecting-patients-and-the-nhs-through-full-transparency-in-industry-nhs-collaborations.pdf>
19. Lexchin J, Fugh-Berman A. A Ray of Sunshine: Transparency in Physician-Industry Relationships Is Not Enough. *J Gen Intern Med* 2021;36:-8. pmid: 33694070. doi: 10.1007/s11606-021-06657-0
20. Benjamin IJ, Valentine CM, Oetgen WJ, et al. 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. *Circulation* 2021;143:-87. pmid: 33974449. doi: 10.1161/CIR.0000000000000963
21. Hauser S, Kappos L, Filippi M, et al. 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005). *Neurology* 2024;102doi: 10.1212/WNL.0000000000205584

22. Mulinari S, Martinon L, Jachiet PA, et al. Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries. *Health Policy* 2021;125:-22. pmid: 34006392. doi: 10.1016/j.healthpol.2021.04.015
23. Ozieranski P, Martinon L, Jachiet PA, et al. Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review. *BMJ Open* 2021;11:e053138. pmid: 34916317. doi: 10.1136/bmjopen-2021-053138